Our Research Team are celebrating the news that they’ll soon be part of a brand-new regional Commercial Research Delivery Centre (CRDC) funded by the National Institute for Health and Care Research, alongside Bradford Teaching Hospitals and The Mid Yorkshire Teaching NHS Trust.
All three trusts will form a collaborative from next April, which will improve access to new treatments in research studies across the region for our patients.
Research and Development Lead, Tracy Wood, pictured in purple in the group image, said: “We were approached to apply for this opportunity on the back of CHFT’s excellent reputation and experience in pharmaceutical research.”
“Being part of the CRDC means we will be able to offer patients within our communities more opportunities to access research trials, opening up new specialty areas, and testing new potential treatments across our geographical area.”
“We will have access to more research trials due to our partnership, which will enable our patients to take part in clinical trials that we may not have opened due to strict criteria or rare disease occurrence.”
“As part of the collaborative, we already have respiratory studies in the pipeline, in particular within asthma and COPD to start next April.”
In all, 20 new research hubs will be set up across UK to accelerate research into the next generation of treatments. They will be funded through £100 million of private investment from pharmaceutical companies.
Medical Director, Neeraj Bhasin, said: “I am delighted we have been successful in the process to form a Commercial Research Delivery Centre through collaborating with two of our neighbouring NHS trusts.”
“This means we can conduct clinical trials on a wider scale to offer the patients we care for a potentially broader range of treatments, where appropriate. This also means we can contribute to the development of future, novel treatments with a much larger geographical impact. This is a very positive development for CHFT, the wider NHS, but most importantly, our current and future patients.”